Wednesday, July 8, 2026

Patent intelligence · US

US 10736919

Materials and methods for engineering cells and uses thereof in immuno-oncology

granted A61KA61K2239/31A61K2239/38A61K2239/48
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 65
Patent details — US 10736919
Jurisdiction
US
Status
granted
Grant date
Aug 11, 2020
Expiration
Aug 6, 2040
Claims
11
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48
View on Google Patents ↗

Quick answer

US 10736919 (Materials and methods for engineering cells and uses thereof in immuno-oncology) is held by CRISPR THERAPEUTICS AG. Status: granted. Granted Aug 11, 2020. Expires Aug 6, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
11
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K2239/56, A61K38/00

More from CRISPR THERAPEUTICS AG

Related pharmaceutical patents in our USPTO index.

  1. US 12427170

    Universal donor cells

    CRISPR THERAPEUTICS AG · Expires Sep 25, 2045

    granted
  2. US 12344656

    Genetically engineered T cells having improved persistence in culture

    CRISPR THERAPEUTICS AG · Expires Jun 26, 2045

    granted
  3. US 12344655

    Gene-edited natural killer cells

    CRISPR THERAPEUTICS AG · Expires Jun 26, 2045

    granted
  4. US 12304968

    T-cells expressing anti-LIV1 chimeric antigen receptor

    CRISPR THERAPEUTICS AG · Expires May 15, 2045

    granted
  5. US 12263227

    Optimized mRNA encoding CAS9 for use in LNPs

    CRISPR THERAPEUTICS AG · Expires Mar 27, 2045

    granted
  6. US 12247201

    Materials and methods for treatment of autosomal dominant retinitis pigmentosa

    CRISPR THERAPEUTICS AG · Expires Mar 6, 2045

    granted
  7. US 12241087

    Compositions and methods for differentiating stem cells into NK cells

    CRISPR THERAPEUTICS AG · Expires Feb 27, 2045

    granted
  8. US 12227763

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Expires Feb 13, 2045

    granted

Frequently asked questions

What is US patent 10736919?

US 10736919 (Materials and methods for engineering cells and uses thereof in immuno-oncology) is held by CRISPR THERAPEUTICS AG. Status: granted. Granted Aug 11, 2020. Expires Aug 6, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10736919?

CRISPR THERAPEUTICS AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 65 pharmaceutical patents for this assignee.

When does US 10736919 expire?

Our index shows an expiration date of Aug 6, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.